Achillion rides crest of hepatitis C wave
This article was originally published in Scrip
Executive Summary
Achillion could not have timed it better if it tried. A day after Merck & Co splurged $3.85bn for Idenix Pharmaceuticals' and its 'nucs' in a bid to challenge Gilead Sciences to the hepatitis C crown, comes news that the US FDA has lifted a clinical hold on Achillion's NS3/4A protease inhibitor sovaprevir. The firm has also begun dosing its nuc, ACH-3422, for seven days in patients with genotype 1 chronic hepatitis C. Proof-of-concept results from this trial are expected in the third quarter.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.